Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1887 1
1950 1
1952 3
1953 1
1954 2
1955 2
1956 9
1957 7
1958 2
1959 4
1960 2
1961 1
1962 3
1964 1
1965 3
1966 2
1967 4
1968 2
1969 3
1970 2
1971 2
1972 4
1973 4
1974 2
1975 3
1976 2
1977 3
1978 3
1979 3
1980 7
1981 7
1982 10
1983 12
1984 11
1985 11
1986 9
1987 11
1988 12
1989 23
1990 14
1991 11
1992 15
1993 9
1994 8
1995 8
1996 8
1997 2
1998 8
1999 7
2000 13
2001 21
2002 9
2003 15
2004 19
2005 15
2006 20
2007 20
2008 15
2009 29
2010 16
2011 22
2012 16
2013 18
2014 31
2015 18
2016 26
2017 24
2018 26
2019 25
2020 25
2021 30
2022 24
2023 19
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

740 results

Results by year

Filters applied: . Clear all
Page 1
Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
Paton NI, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh HWL, Molton J, Mortera L, Naval S, Abu Bakar Z, Pang YK, Lum L, Lim TK, Cross GB, Lekurwale G, Choi H, Au V, Connolly J, Hibberd M, Green JA; Pascolizumab Tuberculosis Trial Team. Paton NI, et al. Among authors: green ja. J Infect Dis. 2024 Mar 25:jiae104. doi: 10.1093/infdis/jiae104. Online ahead of print. J Infect Dis. 2024. PMID: 38527849
A framework to unlock marine bird energetics.
Dunn RE, Duckworth J, Green JA. Dunn RE, et al. Among authors: green ja. J Exp Biol. 2023 Dec 15;226(24):jeb246754. doi: 10.1242/jeb.246754. Epub 2023 Dec 18. J Exp Biol. 2023. PMID: 37990955 Free PMC article.
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Mehdipour P, et al. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w. Malar J. 2023. PMID: 37817240 Free PMC article.
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.
Writing Group for the CKD Prognosis Consortium; Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, Alencar de Pinho N, Anderson A, Appel LJ, Ärnlöv J, Azizi F, Bansal N, Bell S, Bilo HJG, Brunskill NJ, Carrero JJ, Chadban S, Chalmers J, Chen J, Ciemins E, Cirillo M, Ebert N, Evans M, Ferreiro A, Fu EL, Fukagawa M, Green JA, Gutierrez OM, Herrington WG, Hwang SJ, Inker LA, Iseki K, Jafar T, Jassal SK, Jha V, Kadota A, Katz R, Köttgen A, Konta T, Kronenberg F, Lee BJ, Lees J, Levin A, Looker HC, Major R, Melzer Cohen C, Mieno M, Miyazaki M, Moranne O, Muraki I, Naimark D, Nitsch D, Oh W, Pena M, Purnell TS, Sabanayagam C, Satoh M, Sawhney S, Schaeffner E, Schöttker B, Shen JI, Shlipak MG, Sinha S, Stengel B, Sumida K, Tonelli M, Valdivielso JM, van Zuilen AD, Visseren FLJ, Wang AY, Wen CP, Wheeler DC, Yatsuya H, Yamagata K, Yang JW, Young A, Zhang H, Zhang L, Levey AS, Gansevoort RT. Writing Group for the CKD Prognosis Consortium, et al. Among authors: green ja. JAMA. 2023 Oct 3;330(13):1266-1277. doi: 10.1001/jama.2023.17002. JAMA. 2023. PMID: 37787795 Free PMC article.
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Ramasamy MN, Kelly EJ, Seegobin S, Dargan PI, Payne R, Libri V, Adam M, Aley PK, Martinez-Alier N, Church A, Jepson B, Khan M, Matthews S, Townsend GT, Vekemans J, Bibi S, Swanson PA 2nd, Lambe T, Pangalos MN, Villafana T, Pollard AJ, Green JA; AZD2816 Study Group. Ramasamy MN, et al. Among authors: green ja. Lancet Microbe. 2023 Nov;4(11):e863-e874. doi: 10.1016/S2666-5247(23)00177-5. Epub 2023 Sep 29. Lancet Microbe. 2023. PMID: 37783221 Free article. Clinical Trial.
740 results